Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.37 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.34 |
| ▸ | NT5M | Q9NPB1 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | TK2 | O00142 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1054675 | 0.91 | TDP1 (0.34) | — | |
| SCHEMBL16648575 | 0.87 | TK1 (0.38) | TK1RNASE1NT5MBCHETK2 | |
| SCHEMBL20394055 | 0.86 | TK1 (0.37) | TK1RNASE1NT5MBCHETK2 | |
| SCHEMBL28749276 | 0.86 | TK1 (0.37) | TK1RNASE1NT5MBCHETK2 | |
| SCHEMBL20394057 | 0.86 | TK1 (0.37) | TK1RNASE1NT5MBCHETK2 | |
| SCHEMBL23152969 | 0.85 | TK2 (0.39) | TK1RNASE1NT5MBCHETK2 | |
| SCHEMBL23152977 | 0.85 | TK1 (0.41) | TK1RNASE1NT5MBCHETK2 | |
| SCHEMBL23152967 | 0.85 | TK1 (0.38) | TK1RNASE1NT5MBCHETK2 | |
| SCHEMBL1097107 | 0.85 | TK1 (0.37) | TK1NT5MTK2 | |
| SCHEMBL1097256 | 0.84 | TK1 (0.39) | TK1RNASE1NT5MBCHETK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957201-B2 | Oligonucleotide analogues and methods utilizing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| US-20110009471-A1 | Oligonucleotide analogues and methods utilizing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-7816333-B2 | Oligonucleotide analogues and methods utilizing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-10-19 | — | — | US | disclosed |
| US-20090149404-A1 | Oligonucleotide analogues and methods utilizing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-06-11 | — | — | US | disclosed |
| US-7335765-B2 | Nucleoside and oligonucleotide analogues | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-02-26 | — | — | US | disclosed |
| US-7314923-B2 | Nucleoside and oligonucleotide analogues | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-01-01 | — | — | US | disclosed |
| US-20030207841-A1 | Novel nucleoside and oligonucleotide analogues | SANKYO COMPANY LIMITED (JP) | 2003-11-06 | — | — | US | disclosed |
| US-20020147332-A1 | Novel nucleoside and oligonucleotide analogues | SANKYO COMPANY, LIMITED (JP) | 2002-10-10 | — | — | US | disclosed |
| EP-1152009-A1 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | Sankyo Company, Limited (JP) | 2001-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009471-A1 | Oligonucleotide analogues and methods utilizing the same | NSUN2, RNGTT, DUT | TK1 52/4885RNASE1 17/4885NT5M 586/4885 |
| US-20020147332-A1 | Novel nucleoside and oligonucleotide analogues | RNGTT, NSUN2, MTAP | TK1 91/4885RNASE1 43/4885NT5M 542/4885 |
| US-20090149404-A1 | Oligonucleotide analogues and methods utilizing the same | NSUN2, RNGTT, DUT | TK1 52/4885RNASE1 17/4885NT5M 586/4885 |
| US-20030207841-A1 | Novel nucleoside and oligonucleotide analogues | RNGTT, NSUN2, MTAP | TK1 91/4885RNASE1 43/4885NT5M 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.